How Benitec’s ddRNAi technology can overcome the challenges of siRNA-based methods.




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: How Benitec’s ddRNAi technology can overcome the challenges of siRNA-based methods.
Released on: January 12, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Georgina Kilfoil, Chief Clinical Officer of Benitec Biopharma, discusses Benitec’s unique gene-silencing technology.
  • Summary
  • Transcript
  • Participants
  • Company
Georgina Kilfoil, Chief Clinical Officer of Benitec Biopharma, discusses Benitec’s unique gene-silencing technology.
Georgina Kilfoil, Chief Clinical Officer of Benitec Biopharma, discusses Benitec’s unique gene-silencing technology.
Georgina Kilfoil has over twenty-five years of drug development, project management and clinical research experience. Prior to joining Benitec Biopharma, Ms. Kilfoil has been a Senior Drug Development Consultant providing strategic development advice in multiple therapeutic areas and across all phases of drug development and was SVP, Development at Anthera Pharmaceuticals. Ms. Kilfoil served as Vice-President, Alliances and Project Management at Peninsula Pharmaceuticals where she played a key role in the development and successful NDA filing for Doribax®. Prior to Peninsula Pharmaceuticals, Ms Kilfoil was a project management consultant for Vicuron Pharmaceuticals and played an instrumental role in the development and successful NDA filing of Eraxis®. Ms Kilfoil is a certified Project Management Professional, has a Bachelor of Science Degree in Pharmacology from the University of Bristol, United Kingdom, and a Masters of Business Administration from the Australian Graduate School of Management, Sydney, Australia.
Benitec
Benitec's technology has broad applicability to all medical conditions where the permanent silencing of specific genes is indicated for treatment. The Company is initially addressing multi-billion dollar market opportunities in hepatitis B, lung cancer and cancer-associated neuropathic pain. The technology is potentially applicable to over 22,000 human genes and a much larger number of genes in disease-causing micro-organisms. Benitec's ddRNAi technology has been clinically tested in a pilot Phase I/II clinical trial on HIV/AIDS-related lymphoma patients and was proven to be safe and feasible